Lung cancer trials in Italy

In Italy 272 Also abroad 2746

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Where
Milan, Rome
Age
18 years and over
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Ancona, Candiolo, Meldola, Ravenna, Roma, Verona
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 2Taking people
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Where
Aviano, Meldola, Milan, Orbassano, Padova, Rome, Rozzano
Age
18 years and over
People
278 worldwide
Run by
AstraZeneca
See details and how to joinNCT07098338 · EU 2025-524843-11-00
Phase 1Taking people
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Where
Bologna, Candiolo, Naples, Rozzano, Verona
Age
18 years and over
People
300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00
Phase 3Taking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Avellino, Aviano, Cremona, Lucca, Meldola, Monza, Naples, Peschiera del Garda
Age
18 years and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
Phase 2Taking people
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
Where
Cremona, Florence, Meldola, Milan, Parma, Ravenna
Age
18 years and over
People
117 worldwide
Run by
Taiho Oncology Inc.
See details and how to join2023-503865-48-00
Phase 2/3Not yet taking people in Italy
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Where
Avellino, Aviano, Candiolo, Milan, Naples, Orbassano, Parma, Ravenna
Age
18 years and over
People
173 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Milan, Modena, Roma
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 1/2Taking people
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Where
Milan, Rome, Rozzano
Age
18 years and over
People
554 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00
Phase 3Taking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Alexandria, Ancona, Bergamo, Bologna, Candiolo, Catania, Leghorn, Legnano, Meldola, Milan, Modena, Naples, Orbassano, Pavia, Peschiera del Garda, Ravenna, Rome, Siena, Verona
Age
18 years and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
Phase 2Not yet taking people in Italy
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Where
Aviano, Peschiera del Garda, Turin
Age
18 years and over
People
80 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07871214
Phase 1Taking people
Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
Where
Meldola, Milan, Orbassano, Ravenna, Rome
Age
18 years and over
People
330 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509571-16-00
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Meldola, Milan, Naples, Roma, Rozzano
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 2Taking people
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Where
Bergamo, Milan, Orbassano, Rome
Age
18 years and over
People
40 worldwide
Run by
Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00
No phaseNot yet taking people in Italy
Dermatological Effects and Quality of Life in Oncology Patients
Where
Milan
Age
18 years and over
People
300
Run by
European Institute of Oncology
See details and how to joinNCT07869186
Phase 2Taking people
Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial
Where
Milan
Age
18 years and over
People
26
Run by
Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2022-502253-34-00
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Aviano, Brescia, Fano, Florence, Genoa, Meldola, Milan, Misterbianco, Naples, Parma, Ravenna, Rome, Verona
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2/3Taking people
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Where
Aviano, Orbassano, Rome
Age
18 years and over
People
550 worldwide
Run by
Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00
Phase 1/2Taking people
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Where
Fano, Roma
Age
18 years and over
People
162 worldwide
Run by
Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Milan, Negrar, Peschiera del Garda, Rome
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aviano, Genoa, Leghorn, Milan, Misterbianco, Modena, Monza, Naples, Pesaro, Peschiera del Garda, Rome, Taranto, Trento
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00
Phase 2Taking people
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Where
Cremona, Florence, Meldola, Milan, Parma, Ravenna
Age
18 years and over
People
220 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT05967689
Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Orbassano, Perugia, Roma, Rome
Age
18 years and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Aviano, Candiolo, Catania, Fano, Milan, Monza, Naples, Rome, Verona
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750